The mechanism of action, pharmacokinetics, and clinical efficacy of carfilzomib for the treatment of multiple myeloma

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Expert Opinion on Drug Metabolism & Toxicology

• Publication date

  2013-09-14

• Fields of study

  Medicine

• Identifiers
  DOI 10.1517/17425255.2013.817556PMID 23834482
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Clinical Pharmacokinetics, Metabolism, and Drug-Drug Interaction of Carfilzomib

  2013influential reference
• Phase Ib Dose-Escalation Study (PX-171-006) of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Progressive Multiple Myeloma

  2013cited by this paper
• Carfilzomib: A new proteasome inhibitor for relapsed or refractory multiple myeloma

  2013cited by this paper
• The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects

  2013cited by this paper
• An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma.

  2012cited by this paper
• A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma.

  2012cited by this paper
• A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma.

  2012cited by this paper
• A Phase I Single-Agent Study of Twice-Weekly Consecutive-Day Dosing of the Proteasome Inhibitor Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma or Lymphoma

  2012cited by this paper
• Phase 1/1b Study of the Efficacy and Safety of the Combination of Panobinostat + Carfilzomib in Patients with Relapsed and/or Refractory Multiple Myeloma

  2012cited by this paper
• Carfilzomib, Cyclophosphamide and Dexamethasone (CCd) for Newly Diagnosed Multiple Myeloma (MM) Patients

  2012cited by this paper
• An open‐label, single‐arm, phase 2 study of single‐agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib

  2012cited by this paper
• Results From the Phase II Dose Expansion of Cyclophosphamide, Carfilzomib, Thalidomide and Dexamethasone (CYCLONE) in Patients with Newly Diagnosed Multiple Myeloma

  2012cited by this paper
• Carfilzomib Combined with Thalidomide and Dexamethasone (CTD) Is an Highly Effective Induction and Consolidation Treatment in Newly Diagnosed Patients with Multiple Myeloma (MM) Who Are Transplant Candidate

  2012cited by this paper
• A Multi-Center Phase I/II Trial of Carfilzomib and Pomalidomide with Dexamethasone (Car-Pom-d) in Patients with Relapsed/Refractory Multiple Myeloma

  2012cited by this paper
• Integrated Safety From Phase 2 Studies of Monotherapy Carfilzomib in Patients with Relapsed and Refractory Multiple Myeloma (MM): An Updated Analysis

  2011cited by this paper
• Pharmacokinetics, Pharmacodynamics, Metabolism, Distribution, and Excretion of Carfilzomib in Rats

  2011cited by this paper
• Phase II study of carfilzomib in patients with relapsed/refractory multiple myeloma and renal insufficiency.

  2010cited by this paper
• How to treat elderly patients with multiple myeloma: combination of therapy or sequencing.

  2009cited by this paper
• A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of the Novel Proteasome Inhibitor Carfilzomib (PR-171) in Patients with Hematologic Malignancies

  2009influential reference
• Phase I Study of Carfilzomib in Patients (Pts) with Relapsed and Refractory Multiple Myeloma (MM) and Varying Degrees of Renal Insufficiency.

  2009cited by this paper
• Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome.

  2007cited by this paper
• Total synthesis of the potent proteasome inhibitor epoxomicin: a useful tool for understanding proteasome biology.

  1999cited by this paper
• Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity.

  1999cited by this paper
• Epoxomicin, a new antitumor agent of microbial origin.

  1992cited by this paper

• Development of Orally Bioavailable Octahydroindole-Based Peptidomimetic Derivative as a Broad-Spectrum Inhibitor against HCoV-OC43 and SARS-CoV-2.

  2025cites this paper
• Population pharmacokinetic/pharmacodynamic joint modeling of ixazomib efficacy and safety using data from the pivotal phase III TOURMALINE‐MM1 study in multiple myeloma patients

  2022cites this paper
• Targeting nutrient metabolism with FDA-approved drugs for cancer chemoprevention: Drugs and mechanisms.

  2021cites this paper
• KD-PACE Salvage Therapy for Aggressive Relapsed Refractory Multiple Myeloma, Plasma Cell Leukemia and Extramedullary Myeloma.

  2021cites this paper
• Pharmacological characterization of a novel metal-based proteasome inhibitor Na-AuPT for cancer treatment

  2021cites this paper
• A6 Peptide-Tagged Core-Disulfide-Crosslinked Micelles for Targeted Delivery of Proteasome Inhibitor Carfilzomib to Multiple Myeloma in Vivo.

  2020cites this paper
• Pharmacodynamics and pharmacokinetics of proteasome inhibitors for the treatment of multiple myeloma

  2019cites this paper
• Prospective Study of Cardiac Events During Proteasome Inhibitor Therapy for Relapsed Multiple Myeloma.

  2019cites this paper
• The Host Protein Reticulon 3.1A Is Utilized by Flaviviruses to Facilitate Membrane Remodelling.

  2017cites this paper
• PU-H71: An improvement on nature's solutions to oncogenic Hsp90 addiction.

  2015cites this paper
• Carfilzomib enhances natural killer cell-mediated lysis of myeloma linked with decreasing expression of HLA class I

  2015cites this paper
• Thrombotic microangiopathy associated with proteasome inhibitors

  2015cites this paper
• Panobinostat: a novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myeloma

  2015cites this paper
• Stress Response Pathways in Cancer

  2015cites this paper
• PU-H 71 : An improvement on nature ’ s solutions to oncogenic Hsp 90 addiction

  2015cites this paper
• Anti-tumor activity of the proteasome inhibitor BSc2118 against human multiple myeloma.

  2015cites this paper
• The Ubiquitin-Proteasome System (UPS) as a Cancer Drug Target: Emerging Mechanisms and Therapeutics

  2014cites this paper
• Natural product and natural product derived drugs in clinical trials.

  2014cites this paper
• Evaluation of tubulin polymerization and chronic inhibition of proteasome as citotoxicity mechanisms in bortezomib-induced peripheral neuropathy

  2014cites this paper